Anti-Asthmatic Agents ; therapeutic use ; Asthma ; drug therapy ; physiopathology ; Chronic Disease ; Humans ; Long-Term Care ; Lung ; physiopathology ; Respiratory Function Tests ; Severity of Illness Index ; Treatment Outcome

Small cell lung cancer(SCLC)is regarded as one of the most chemotherapy and radiotherapy sensitive malignant solid tumors.With regimens based on platinum-etoposide,which is still the standard of first-line treatment in extensive-stage SCLC,objective responses are seen in 50% to 70% of cases.With combined chemoradiotherapy,the probability of attaining a complete response increases to 40% to 50%.The majority of patients with SCLC will eventually develop a tumor relapse.For the patients with relapse,so far only single-agent topotecan represents a most effective therapeutic option.Integration of chest radiotherapy with standard chemotherapy,optimization of timing and fractionation of radiation therapy,and the introduction of prophylactic cranial radiation have led to an obvious improvement in 3-year survival.

ObjectiveTo study the effect of of oral powered microdedrider adenoidectomy with nasal endoscope in children with secretory otitis media. Methods74 children with secrctory otitis media treated with adenoidectomy with nasal endoscope randomly divided into group A 37 cases and group B 37 cases,the group A were treated with trans-oral adenoidectomy under endoscope, the group B were treated with trans-nasal adenoidectomy under endoscope,then the total effective rate,operation time, blood loss,incidence of complications and serum IgE, NO, IL-6,TNF-αand IL-2 of the two groups before and after the treatment were compared. ResultsThe cure, effective, and ineffective of group A were 34 cases ,3cases and 0 cases ,the total effective rate was 100.0％, the cure, effective,and ineffective of group B were 26 cases,7 cases and 4 cases,the total effective rate was 89.2％ ,the total effective rate of group A was significantly higher than that of group B( x2 =6. 869 ,P ＜0.05 ) ,the operation time of group A was( 8.6± 1.6) min, blood loss was( 12.3 ± 4. 1 ) ml, incidence of complications was 2.7％ ( 1 case postoperative hemorrhage), operation time of group B was ( 14.2 ± 2.1 ) min, blood loss was( 17.8 ± 3.5 ) ml, incidence of complications was 10.8％ (2 cases nasal adhesion and 2 cases postoperative hemorrhage) ,there were significant differences between the two groups ( t =5. 967,6.553, x2 =7. 142, all P ＜ 0.05 ), serum IgE, NO, IL-6,TNF-αand IL-2of the group A after the treatment were all lower than those of group B, ( t =5. 557,6. 348,5. 968,6. 976,5. 884, all P ＜ 0. 05 ).ConclusionThe effect of oral powered microdedrider adenoidectomy with nasal endoscope in children with secretory otitis media better,and it was worthy of popularization and application.

ObjectiveTo study the relationship between human papilloma virus(HPV) infections,p53 polymorphisms and esophageal cancer.MethodsA case-control study of 204 esophageal cancer cases (esophageal cancer group) and 102 healthy control cases (control group) biopsies were conducted to extract DNA,detected the HPV by PCR method and analyzed p53 polymorphisms by PCR-RFLP method,then analyzed the relationship between them and esophageal cancer incidence rate.ResultsThe positive rate of HPV16 in esophageal cancer group[59.3％(121/204)] was higher than that in control group [11.8％ ( 12/102 ) ] (P ＜ 0.05 ).And the frequency of Arg/Arg genttype of p53 in esophageal cancer group [ 51.5％ (105/204) ] was higher than that in control group [ 19.6％ (20/102) ] (P ＜ 0.05 ).The frequency of Arg/Arg genotypo in HPV16 positive patients [66.9％(81/121 )] was higher than that in HPV16 negative patients [ 28.9％ (24/83)] (P ＜ 0.05).ConclusionsHigh risk HPV phys an important role in development of esophageal cancer,p53 Arg/Arg genotype is one of high risk genetic factors for HPV-associated esophageal cancer.

AIM: To study the expression of matrix metalloproteinase-9 (MMP-9) in human bronchial epithelial cell treated with TNF-?, ConA and mechanical injury. METHODS: RT-PCR and gelatin zymography were performed to observe the dynamic expression of matrix metalloproteinase-9(MMP-9) in human bronchial epithelial cell line H292 at different timepoint(2 h, 6 h,12 h, 24 h) after stimulation with TNF-?, ConA and mechanical injury. RESULTS: Human bronchial epithelial cell H292 expressed and secreted matrix metalloproteinase-9 in the presence of TNF-?, ConA and mechanical injury. On stimulation with mechanical injury alone, MMP-9 was initially expressed at 2 h, peaked at 12 h, and decreased at 24 h. Furthermore, on stimulation with combination of ConA and mechanical injury, the MMP-9 mRNA expression was the highest among in all the groups. Zymography show that the MMP-9 activity appeared just at 24 h timepoint, and was highest at the group of combination of ConA and mechanical injury. CONCLUTION: Human bronchial epithelial cell expressed and secreted MMP-9 when treated with TNF-?, ConA and mechanical injury.

Objective To investigate the in vitro effect of low dosage of paclitaxel on normal murine bone marrow-derived dendritic cells(mDCs)and its role in reactivating tumor-pulsed DCs. Methods The concentration of paclitaxel which could induce 30% apoptosis of 3LL cell lines was figured out.mDCs were generated from murine bone marrow precursors.Cell culture insert system was used and four groups were divided as following: mDC,mDC+3LL,mDC+ low dose of paclitaxel,and mDC+3LL with 30% apoptosis induced by low dose of paclitaxel.The phenotypes,chemoattractive function to MIP1? and MIP-3?,and viability in activating allogeneic T cell proliferation of DCs in the four groups were analysed. Results Paclitaxel of 50 nmol/L could induce 30% apoptosis of 3LL,and had protective effects on DCs.It could stimulate the maturation of mDCs by up-regulating the phenotypes of CD11cCD80,CD11cCD86,CD11cCD40 and CD11cCDIab,and could enhance the chemoattractive function to chemokine MIP-3?.Compared with those cocultured with 3LL,DCs pulsed with apoptosis antigen of 3LL cell which was induced by 50 nmol/L paclitaxl up-regulated the phenotype of CD11cCD40,enhanced the the chemoattractive function to MIP1? and MIP-3?,and activated the proliferation of T cells. Conclusion Paclitaxel of 50 nmol/L can stimulate the maturation of DC,and can partially recover the phenotype and function of tumor-pulsed DC.

Objective To investigate the role of clinical pharmacist in medical therapy for a patient with cerebrovascular disease and epilepsy.Methods One patient was hospitalized due to headache and twitch.Clinical diagnosis was cerebral venous sinus thrombosis and epilepsy.During the treatment,the clinical pharmacist gave suggestion on drug selection of anti-infection and anti-epileptic therapy,assessed drug interaction between omeprazole-escitalopram and mannitoldexamethasone,monitored the adverse drug reaction of valproate,and provided medication education to the patient.Results Physician adopted clinical pharmacist's suggestion.The patient discharged with stable condition.Conclusion The participation of clinical pharmacists in the medication therapy of patients with cerebrovascular disease can reduce the risk of drug use and promote the efficacy and safety of medication.

Objective To study the threshold effect of government health expenditure on residents' health.Methods Using threshold panel data model to perform the empirical research.Results There is threshold effect of government health expenditure on residents' health.There are two threshold values.As the increase of the proportion of the government health expenditure to the total fiscal expenditure,it has two changes of the impact on the health of residents.Conclusion The government should increase the health expenditure,and increase the proportion of the government health expenditure to the total fiscal expenditure,but the government should not blindly pursue the high input of health expenditure,focus on the efficiency of health expenditure,and avoid of resource waste.

It has always been controversial whether a single allergen performs better than multiple allergens in polysensitized patients during the allergen-specific immunotherapy.This study aimed to examine the clinical efficacy of single-allergen sublingual immunotherapy (SLIT) versus multi-allergen subcutaneous immunotherapy (SCIT) and to discover the change of the biomarker IL-4 after 1-year immunotherapy in polysensitized children aged 6-13 years with allergic rhinitis (AR) induced by house dust mites (HDMs).The AR polysensitized children (n=78) were randomly divided into two groups:SLIT group and SCIT group.Patients in the SLIT group sublingually received a single HDM extract and those in the SCIT group were subcutaneously given multiple-allergen extracts (HDM in combination with other clinically relevant allergen extracts).Before and 1 year after the allergen-specific immunotherapy (ASIT),the total nasal symptom scores (TNSS),total medication scores (TMS) and IL-4 levels in peripheral blood mononuclear cells (PBMCs) were compared respectively between the two groups.The results showed that the TNSS were greatly improved,and the TMS and IL-4 levels were significantly decreased after 1-year ASIT in both groups (SLIT group:P＜0.001;SCIT group:P＜0.001).There were no significant differences in any outcome measures between the two groups (for TNSS:P＞0.05;for TMS:P＞0.05;for IL-4 levels:P＞0.05).It was concluded that the clinical efficacy of single-allergen SLIT is comparable with that of multi-allergen SCIT in 6-13-year-old children with HDM-induced AR.

Purpose: To evaluate the clinical efficacy of V AD regimen in the treatment of newly diagnosed stage III multiple myeloma (MM). Methods:26 patients with newly diagnosed stage Ⅲ multiple myel oma were treated with VAD regimen. VAD solution consisted of vincristine (VCR) , doxorubicin(ADR),dexamethasone (Dex).Three continuous treatments in one treatm ent course were considered evaluable.Evaluation included results of serum myelom a protein(M-protein); renal function; proteinuria of 24-hours; bone marrow ; per ipheral blood et al.The side reactions were recorded. The clinical efficacy eval uation was divide into complete response(CR),partial response(PR),minimal-respon se(MR), no change(NC) , plateau progression.Results:5 cases achieved CR(19.3%), 13 cases PR(50%),6 case s MR (23%), 2 cases no change (7.7%). Overall response rate was 92.3%, median su rvival duration was 7 to 84 months (29.6?17months). Conclusions:Achieved marked clinical efficacy with VAD agent in newly diagnosed stage III multiple myeloma. Especially,the patients with renal failure and serious clinical manifestation improved rapidly and significantly.